hVIVO engages in major phase 2b influeness drug study as exclusive UK clinical site
hVIVO plc (AIM & Euronext: HVO), a rapidly expanding specialist contract research organisation (CRO) renowned for its expertise in human challenge clinical trials for infectious and respiratory diseases, has announced its latest engagement in a significant Phase 2b field study. The study will assess an influenza drug candidate, marking a milestone as hVIVO’s largest field […]